By admin 
When Stephen Rosenfeld and Patricia Seymour founded the not-for-profit North Star Review Board, they had become profoundly disillusioned with the scientific oversight system in America, a framework they believed had prioritized institutional efficiency over the very lives it was designed to protect. Institutional Review Boards, or IRBs, are mandated by federal law to serve as the final gatekeepers of clinical research, with a single, uncompromising priority: the rights, safety, and welfare of human research participants. However, after decades serving as research ethicists and high-level administrators within the industry, Rosenfeld and Seymour concluded that the oversight sector had lost its ethical compass, drifting toward a corporate "customer service" model that treats researchers as clients and participants as data points.
The crisis within the IRB system is not merely a matter of theoretical debate among academics; it is a structural failure that has been documented through decades of scandals and federal investigations. Experts suggest that the fundamental problem lies in a system that allows—and often encourages—financial interests to overlap with ethical oversight. A landmark example of this vulnerability occurred in 2009, when the Government Accountability Office (GAO) conducted a "sting" operation to determine if for-profit IRBs could detect a blatantly unethical and fraudulent research protocol. The GAO created a fictitious medical device and a bogus application that matched several criteria for "significant risk" under Food and Drug Administration (FDA) guidance. Despite these red flags, Coast IRB in Colorado approved the application. The resulting report revealed a systemic susceptibility to "unethical manipulation," proving that for-profit boards could be incentivized to approve dangerous research to maintain their revenue streams.
While Coast IRB was eventually shuttered, the systemic reforms many hoped for never materialized. According to ethicists speaking with STAT, the core conflict remains: IRBs are often paid by the very entities they are supposed to regulate. "I felt that the people running IRBs should be focused on its oversight and ethical mission, not necessarily investor returns," Rosenfeld explained. He noted the inherent difficulty in designing a system that is self-funding but free from structural conflicts of interest. The issue, he argues, is not necessarily "bad actors" in the traditional sense, but a regulatory environment that forces ethics into a collision course with the bottom line.
Before any clinical trial or human subject study can begin in the United States, it must receive a stamp of approval from an IRB. These boards were envisioned as a safety net, ensuring that participants—often vulnerable patients seeking experimental cures—can engage with science without fear of exploitation. For the most part, these boards successfully mitigate direct physical harms, such as preventing the administration of known toxins. However, as the business of science has evolved, the oversight mechanism has shifted its focus. Today, the success of an IRB is often measured by its "turnaround time" and its ability to help a sponsor meet legal requirements as quickly as possible, rather than its willingness to challenge the ethical nuances of a study.
This shift is largely driven by the intense financial pressures currently facing research institutions. Universities, once the bastions of independent oversight, are experiencing historic financial instability and are increasingly reliant on massive corporate grants. This has created a "customer service" model of ethics. Holly Fernandez Lynch, an associate professor of medical ethics at the University of Pennsylvania, noted that the investigator is now often viewed as the "customer." When the primary goal becomes speed and legal compliance, IRBs are pressured to approve research that meets the "minimal legal acceptable" standard, even if it falls short of the highest ethical ideals.
This widening gap between the law and ethics is particularly dangerous as technology outpaces regulation. Modern research often involves "informational harms"—concerns regarding data privacy, genetic exploitation, and the long-term use of biological samples—that the current regulatory framework, largely established in the 1970s, was never designed to address. Rosenfeld warns that if the public begins to fear that their participation in a survey or a trial will lead to their data being exploited for profit, the resulting loss of trust could cripple scientific progress for a generation.
The roots of this troubled system can be traced back to the mid-20th century. Laura Stark, a science historian at Vanderbilt University and author of Behind Closed Doors: IRBs and the Making of Ethical Research, argues that the current model was born out of a desire to "pass the buck" on legal liability. During the post-WWII era, the National Institutes of Health (NIH) saw its budget explode from $65 million to over $1 billion. With this growth came a massive increase in extramural research programs. Federal officials realized that if the NIH were held legally responsible for every unethical act committed by a researcher at a distant university, the financial risk to the government would be catastrophic.
Liability, as Stark puts it, became a "hot potato." At the same time, the scientific community resisted external regulation, preferring "voluntary agreements" and industry-written ethics codes—much like the self-regulation currently being proposed by the AI industry. The tipping point was the revelation of the Tuskegee syphilis study, where the U.S. Public Health Service spent 40 years deliberately withholding treatment from Black men to observe the progression of the disease. In the wake of this atrocity, Congress passed the National Research Act of 1974. Lawmakers faced a choice: create a single federal oversight body or decentralize the risk. They chose the latter, saddling local universities and private organizations with the financial and legal responsibility of reviewing research.
This decentralization paved the way for the rise of commercial, private-equity-owned IRBs like Advarra and WCG. These entities allow universities to outsource the "hot potato" of liability. While representatives from these companies, such as Advarra CEO Gadi Saarony, maintain that they are driven by the same mission to safeguard participants and that all boards are held to the same federal standards, critics remain skeptical. They point to high-profile failures that resulted in massive settlements, such as the 2001 death of Ellen Roche at Johns Hopkins and the 2000 death of Jesse Gelsinger at the University of Pennsylvania. These tragedies, Rosenfeld argues, only reinforced the system’s obsession with legal compliance over proactive ethical inquiry.
The current system has been described by Carl Elliott, an ethicist at the University of Minnesota and author of The Occasional Human Sacrifice, as an "honor system" that is fundamentally "crazy." In a multibillion-dollar, for-profit research enterprise, federal bodies like the FDA and the Office for Human Research Protections (OHRP) essentially trust researchers to be honest. This trust is often misplaced. Because local IRBs are frequently composed of the researcher’s own colleagues and faculty members, personal and institutional conflicts of interest are baked into the process. There is an "implicit pressure" to ensure the research proceeds, as any delay could threaten a university’s operating budget or a pharmaceutical company’s stock price.
Elliott, who became a whistleblower in the case of Dan Markingson—a young man who died by suicide after being pressured into an antipsychotic drug trial at the University of Minnesota—highlights the SFBC International scandal of 2006 as a prime example of systemic failure. In that case, a contract research organization (CRO) was recruiting undocumented immigrants for Phase 1 trials and housing them in a condemned Florida motel that was a known fire hazard. Despite these conditions, the research had been cleared by an IRB. Because the review was conducted remotely, no one from the oversight board ever set foot on the trial site. Elliott notes that we regulate restaurants more strictly than we regulate the facilities where experimental drugs are tested on humans.
In response to this environment, North Star Review Board was founded on the principle that removing the profit motive is the first step toward restoring integrity. Patricia Seymour recalls her time working for large for-profit IRBs, noting two specific moments that broke her faith in the industry. During the early days of the COVID-19 pandemic, she observed executives "crowing" about how the crisis allowed them to meet their entire annual budget in a single quarter. In another instance, researchers who discovered a safety issue were hesitant to ask the IRB for a protocol modification because the for-profit board charged a fee for every single interaction, and the researchers’ budget was already exhausted.
North Star aims to do things differently by charging flat annual fees and fostering deep engagement between the board and investigators. While some critics, including Elliott, argue that even a non-profit IRB must compete in a marketplace and is therefore subject to the same pressures, Seymour and Rosenfeld emphasize that their organization is not owned by shareholders and provides only minimal salaries to its founders.
Ultimately, the future of human research oversight remains uncertain. While Rosenfeld envisions an ideal system similar to the FDA’s review process—where user fees are distributed through a neutral government entity representing the public interest—the current political climate makes such a transformation unlikely. The OHRP, the federal body responsible for regulating IRBs, recently saw its staff cut by more than half due to budget reductions and resignations. With the regulatory "watchdog" running on fumes, the burden of ethical leadership falls on smaller, independent entities. For North Star, the mission remains clear: to give a voice to the research participant in a market that has long treated them as an afterthought. As science moves into increasingly complex territory involving genetic data and artificial intelligence, the need for a truly independent, ethically-driven "North Star" has never been more urgent.
